Customer Logins

Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.

Customer Logins

PharmOnline International (POLI)

Set the optimal pharmaceutical product price and identify pricing opportunities across the product life cycle

Pressed to make informed global pharmaceutical pricing decisions? Need to negotiate or defend the price and reimbursement of your product, or explore pricing strategies and opportunities?

POLI is the leading global pharmaceutical pricing database trusted by pricing executives, payors and associations around the world. This highly intuitive tool and data browser allows you to make one-click comparisons of drug prices, launch timelines and reimbursement across 80 countries. Our therapeutic module provides insights over therapeutic costs, approval dates and HTA decisions at indication level.With advanced business reporting tools and analytics, POLI provides unparalleled insights into key pricing drivers, impact of generics, biosimilars and parallel trade, launch sequence analysis, pricing opportunities, and defensive pricing strategies.

POLI can be used to:

  • Analyze and monitor the competitive pricing environment
  • Create strategic pharmaceutical pricing, launch sequence and IRP models
  • Determine optimum post-Loss of Exclusivity (LoE) strategy and pricing opportunities
  • Support dossier submissions and pricing negotiations
  • Assess business impact of International Reference Pricing (IRP) and other P&R events
  • View aggregate indicators and analytics, broken down by therapeutic class or product classification
  • Compare and chart pharmaceutical prices and therapeutic costs at current prices or over time
  • Save time by using our therapeutic cost calculator

What’s Included


Easily make cross-country P&R comparisons across more than 80 developed and emerging markets. Our data uses a consistent methodology across each market.

  • Ex-factory, wholesale, pharmacy and retail prices
  • Therapeutic areas
  • Company portfolio insight
  • Historical pharma pricing data
  • Time-to-market and reimbursement rate data
  • Indication-specific cost data based on detailed assumptions on induction/maintenance dosing, average duration of use, average weight/body surface area and more
  • Indication-specific HTA/reimbursement data, including the clinical data used to support dossier submissions and tracking clinical trials of future therapies

Click to enlarge

  • POLI indicators analytics and charts on time-to-launch, launch sequence, reimbursement list size, average price cuts and more.
  • Aggregate analytics on therapeutic classes, orphan disease products, breakthrough therapies, parallel traded products, generics, branded generics, biosimilars, vaccines, medical devices and more
  • Compare drug prices and costs at current prices and over time
  • Therapy view option which breaks down price data into the specific cost of a drug in any given disease (eg. lung cancer versus colorectal cancer) based on dosing, average duration of use and other detailed assumptions
  • Get pricing history with advanced charting functionality, current price comparisons in selected currency and time series download
  • Instant email notifications of price changes for the products/countries/therapeutic areas selected
  • Daily currency conversion
  • Data browser to create bespoke analytics
  • Expert Access: Timely response and assistance from our team of pricing and reimbursement country analysts and health economic experts
Delivery Options

Maximize your subscription content with IHS Markit Connect – our online customer platform. Connect is a one-stop solution for data searching and discovery, charting, downloading and saving for future use.

  • Filter by price change time periods
  • Download price history in time series
  • Month-on-month data makes trend analysis much easier
  • Convert local currency prices to 80 different currencies, with daily rates
  • Price change email alerts list which geographies and presentations have seen price changes, and in which direction
  • Indicators from raw prices for price trends, time to market and reimbursement list size (for full 80-country subscribers)

Our API delivers data continuously and reliably directly into your workflow.

  • Representational State Transfer Application Programming (REST) API makes data available via URL addresses (or ‘endpoints’)
  • Provides a foundation on which to build databases, charts, websites, visualizations and CSV files, plus facilities to query and lookup specific data
  • Offers the simplest approach to application integration:
    • Access to the API is instantaneous
    • Provides an interactive web environment for developers to explore API features and review technical documentation
    • Developers can test the API calls interactively in a browser
  • 24/7 monitoring and support is provided
  • Scales horizontally for both datasets and clients, ensuring it can meet present and future demand
  • Built for consistent speed, with carefully selected technologies to ensure the best possible performance

IDDS offers tailored data feeds featuring continuous updating and seamless delivery.

  • Internet Data Delivery System (IDDS) delivers fixed data updates in CSV or XML format to the IHS Markit web servers in real time
  • Metadata includes economic concept, geography, source and frequency
  • Updates pull in data changes only, optimizing load speed
  • Data updates can be scheduled

Solve Your Business Challenge

Challenge Solution
I need to track pharmaceutical pricing across countries and develop pharmaceutical pricing and launch sequencing strategies. Make one-click price comparisons across 80 developed and emerging markets.
I need to understand competitor pricing in different countries. Get continually updated data on pricing, market entrants, approvals and P&R listings.
I need to forecast future price swings and pricing opportunities. Access historical price data to follow disease area trends, compare product/therapeutic area P&R status, and time-to-market access.
I need to understand comparative time-to-market and reimbursement trends. Access average to approval, reimbursement time and time to launch for individual drugs, therapeutic areas, or countries.


Gustav Ando

Mr. Ando oversees the development of IHS Markit's global healthcare outlook analysis that focuses on market access, cost of healthcare and new treatment advances as well as coordinating its ongoing thinking on COVID-19. He heads the research and data teams that produce daily analysis, risk assessment and critical data for the pharmaceutical industry, as well as the consulting team that focuses on disease prevention, workforce and demand healthcare microsimulation models. With more than 15 years of experience in the industry, he is a regular speaker at conferences and is frequently cited by major media publications and national radio and television programs. He is the author and podium presenter of research at numerous academic conferences such as ISPOR. Mr Ando also oversees our global comparative industry group which provide critical long-term forecast perspectives across all industries around the world, as well as our specialised global constructrion group. Mr. Ando holds a postgraduate degree from the University of Uppsala, Sweden, and an undergraduate degree from the University of Durham in the United Kingdom.

View Profile

Floriane Reinaud

Ms. Reinaud manages the PharmOnline International (POLI) and therapeutic module databases. She oversees the global information management team that manages the pharmaceutical pricing, cost and reimbursement data, including product positioning, client support, associated research and consulting projects. Ms. Reinaud is an authority on the impact of P&R policies, market access strategies and specialist topics, including risk-sharing agreements, orphan drugs, generics and biosimilars. She joined the company in 2007 and has over ten years of experience in pricing and reimbursement. Floriane Reinaud studied biology and holds an Master of Science in biochemistry, as well as Master of Science in healthcare marketing. She co-authored a peer-reviewed article that was published in The Journal of Biological Biochemistry. She is fluent in French and English.

View Profile

Milena Izmirlieva

Ms. Izmirlieva heads the Life Sciences research team which comprises senior analysts, analysts and health economists covering developed and

View Profile

Follow IHS Markit Life Sciences on Twitter



Filter Sort